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Objectives: The diagnosis and management of oral cavity cancers are often complicated by the 
uncertainty of which patients will undergo malignant transformation, obligating close surveillance over 
time. However, serial biopsies are undesirable, highly invasive, and subject to inherent issues with poor 
inter-pathologist agreement and unpredictability as a surrogate for malignant transformation and 
clinical outcomes. The goal of this study was to develop and evaluate a Multivariate Analytical Risk Index 
for Oral Cancer (MARIO) with potential to provide non-invasive, sensitive, and quantitative risk 
assessments for monitoring lesion progression. 
Materials and Methods: A series of predictive models were developed and validated using previously 
recorded single-IWﾉﾉ S;デ; aヴﾗﾏ ﾗヴ;ﾉ I┞デﾗﾉﾗｪ┞ ゲ;ﾏヮﾉWゲ ヴWゲ┌ﾉデｷﾐｪ ｷﾐ ; さIﾗﾐデｷﾐ┌ﾗ┌ゲ ヴｷゲﾆ ゲIﾗヴWざく MﾗSWﾉ 
development consisted of: (1) training base classification models for each diagnostic class pair, (2) 
pairwise coupling to obtain diagnostic class probabilities, and (3) a weighted aggregation resulting in a 
continuous MARIO. 
Results and Conclusions: Diagnostic accuracy based on optimized cut-points for the test dataset ranged 
from 76.0% for Benign, to 82.4% for Dysplastic, 89.6% for Malignant, and 97.6% for Normal controls for 
an overall MARIO accuracy of 72.8%. Furthermore, a strong positive relationship with diagnostic severity 
┘;ゲ SWﾏﾗﾐゲデヴ;デWS ふPW;ヴゲﾗﾐげゲ IﾗWaaｷIｷWﾐデ Э ヰくΒヰヵ aﾗヴ デWゲデ S;デ;ゲWデぶ ;ゲ ┘Wﾉﾉ ;ゲ デｴW ;Hｷﾉｷデ┞ ﾗa デｴW MARIO デﾗ 
respond to subtle changes in cell composition. The development of a continuous MARIO for OPMD is 
presented, resulting in a sensitive, accurate, and non-invasive method with potential for enabling 
monitoring disease progression, recurrence, and the need for therapeutic intervention of these lesions.  
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HIGHLIGHTS 
 An accurate continuous Multivariate Analytical Risk Index for Oral Cancer has been developed. 
 Diagnostic accuracy based on optimized cut-points for the test dataset for the four lesion classes 
ranged from 76.0% for Benign, to 82.4% for Dysplastic, 89.6% for Malignant, and 97.6% for Normal 
controls. 
 The approach utilizes noninvasive sampling methodology allowing for dentists and physicians to 






While the incidence and mortality of many types of cancer have declined over the last 50 years, rates 
for oral and pharyngeal cancers (OPC), have seen remarkably little improvement during this same time. 
In the United States, the 5-year survival rate of patients diagnosed with OPC, is currently estimated at 
63%.[1] Oral cavity cancers are predominantly epithelial-derived oral squamous cell carcinomas (OSCC), 
;ﾐS デｴW ﾏ;ﾃﾗヴｷデ┞ ;ヴW ヮヴWIWSWS H┞ さヮヴWI;ﾐIWヴﾗ┌ゲざ ﾉWゲｷﾗﾐゲが デｴﾗ┌ｪｴ ﾗﾐﾉ┞ ; ヴWﾉ;デｷ┗Wﾉ┞ ゲﾏ;ﾉﾉ ヮヴﾗヮﾗヴデｷﾗﾐ 
(approximately 5%) will undergo malignant transformation. The term さﾗヴ;ﾉ ヮﾗデWﾐデｷ;ﾉﾉ┞ ﾏ;ﾉｷｪﾐ;ﾐデ 
SｷゲﾗヴSWヴざ ふOPMDぶ describes an epithelial lesion encountered by a clinician, for which there is no obvious 
benign explanation, and which sufficiently elevates an index of suspicion to indicate biopsy to rule out 
malignancy or epithelial dysplasia. The spectrum of histopathology for OPMDs may be variable, from a 
carcinoma at one end of the spectrum, to carcinoma-in-situ (CIS), to various grades of oral epithelial 
dysplasia (OED - severe, moderate or mild), to benign diagnoses. In general, patients with OPMDs are 
referred to experienced clinicians for management in secondary care settings, such as head and neck 
surgeons, oral and maxillofacial surgeons, and oral medicine specialists.  
The uncertainty of which patients or lesions will transform obligates such clinicians to serially monitor 
patients with OPMDs [2] and to biopsy lesions that have clinically evolved during these surveillance 
intervals. However, serial biopsies are undesirable, highly invasive, and histopathology suffers from 
inherent issues with poor inter-pathologist agreement and unpredictability as a surrogate for malignant 
transformation and clinical outcomes .[3,4]  
New approaches and new diagnostic/adjunctive tools that can provide non-invasive, sensitive, and 
quantitative risk assessments for monitoring the progression of patients with a history of oral cancer 
and/or OPMDs are urgently needed. Recent breakthroughs in artificial intelligence, machine vision, and 
deep learning and their broad application to fields involving human uncertainty and decision-making 
represent a frontier in diagnostic testing. [5,6] A continuous risk score derived from non-invasive 
cytopathological measurements has the potential to aid clinicians in OPMD surveillance by providing 
objective information that could be used for a multitude of applications including monitoring disease 
progression, indicating the need for re-biopsy, lesion mapping, and evaluating a response to 
chemoprevention or other therapeutics.     
Historically, an attempt to create an index for oral dysplasia was made in 1969 by Smith and 
Pindborg by aggregating scores recorded for cellular and molecular features in histopathology slides on a 
1-10 scale resulting in a final range from 0-Αヵが ﾆﾐﾗ┘ﾐ ;ゲ デｴW さWヮｷデｴWﾉｷ;ﾉ S┞ゲヮﾉ;ゲｷ; ｷﾐSW┝ざ ふEDIぶく[7] When 
compared to the 5-stage Brothwell categorical grading system,[8] the EDI was associated with a 47% inter-
observer agreement rate compared to 62% for the Brothwell system.[9] The failed adoption of the EDI 
demonstrates the subjectivity among pathologists in diagnosing oral epithelial dysplasia (OED)[9] and 
emphasizes the need for risk metrics that are based on quantitative measurements free from human bias. 
Using single-cell morphometric, nuclear and biomolecular measurements extracted from non-
invasively collected OPMD cytology samples, this paper explores the development of a Multivariate 
Analytical Risk Index for Oral Cancer (MARIO) that is based on gold-standard histopathology with an added 
rigorous pathology adjudication process and can provide a non-invasive assessment of OPMDs in a 






MATERIALS AND METHODS 
TｴW S;デ; ┌ゲWS ｷﾐ デｴｷゲ ゲデ┌S┞ ┘WヴW ﾗHデ;ｷﾐWS aヴﾗﾏ ; ﾉ;ヴｪW さI┞デﾗﾉﾗｪ┞-on-Iｴｷヮざ S;デ;H;ゲW aヴﾗﾏ ヮ;デｷWﾐデゲ 
with OPMDs paired with adjudicated gold-standard pathology diagnoses. [10] Single-cell data from a total 
of 506 patients were used to develop the MARIO, comprised of 125 Normal/Non-neoplastic, 253 Benign, 
40 mild-Dysplastic, 13 moderate-Dysplastic, 10 severe-Dysplastic, and 65 Malignant lesions, according to 
the 2005 WHO definitions. [10] Details for the construction of the cytology database along with patient 
recruitment information can be found in Abram et al., 2016. [10] Approximately 300 parameters 
describing the morphometric appearance and biomarker staining intensity profiles of each individual cell, 
recorded using the open source software, Cell Profiler,[11] were stored in a MySQL database (Amazon 
Web Services RDS). All data analysis and model development was carried out in the statistical computing 
environment, R (v 3.2.1).[12] While the original study was completed with two sets of statisticians in an 
infrastructure that supported completely blinded transfer and data analysis, the infrastructure was no 
longer available for this current study. However, in the spirit of avoiding data overfitting, the original raw 
data was randomized and a hold-out dataset was reserved using stratified random sampling to achieve 
equal class proportions between the test (25%) and the training (75%) datasets following data imputation, 
scaling, and centering to normalize the effect of different parameters.  
Due to the low number of dysplastic cases commonly observed with prospective OPMD 
ヴWIヴ┌ｷデﾏWﾐデが さﾏｷﾉSざが さﾏﾗSWヴ;デWざが ;ﾐS さゲW┗WヴW S┞ゲヮﾉ;ゲｷ;ざ I;ゲWゲ ┘WヴW ｪヴﾗ┌ヮWS ｷﾐデﾗ ﾗﾐW さD┞ゲヮﾉ;ゲデｷIざ 
category resulting in four diagnostic classes with at least 50 patients each (Normal, Benign, Dysplastic, 
Malignant). The development of the MARIO involved the following steps: (1) training multiple base 
classification models for each class pair, (2) pairwise coupling to obtain class probabilities, and (3) a 
weighted aggregation to obtain a final risk score on a continuous scale. The overall development process 
is summarized in equation form in Supplementary Figure 1. 
Due to the ability of the L1-regularized logistic regression (Lasso) methodology to prevent model 
over-fitting in high-dimensional data sets by iteratively shrinking parameter effect sizes, the Lasso 
technique was utilized in this study to build base classification models. Between the four diagnostic 
classes, a total of six base classification models were developed: Normal/Benign, Normal/Dysplastic, 
Normal/Malignant, Benign/Dysplastic, Benign/Malignant, and Dysplastic/Malignant. Overall error rate 
and mean square error (MSE) representing misclassifications for the six base classification models are 
shown in Supplementary Table 1.  
The pairwise coupling method described by Price et al. (1995) [13] was used to convert base 
classification model scores  into class probabilities for Normal, Benign, Dysplastic, and Malignant classes. 
Since probabilities calculated by this method do not necessarily sum to 1.0, the final class scores were 
normalized by dividing by eacｴ ﾗHゲWヴ┗;デｷﾗﾐげゲ ゲ┌ﾏ ﾗa ゲIﾗヴWゲく This process resulted in a total of four 
probabilities per patient corresponding to the different class definitions (e.g. PNormal = 0.1, PBenign = 0.8, 
PDysplastic = 0.1, and PMalignant = 0.0).  
Finally, the MARIO was computed as a weighted average of the individual class probabilities. 
Class weights were implemented to account for the increase in severity in the ordered diagnoses from 
Normal through Benign, Dysplastic, and Malignant classes and were determined through an iterative 
process to maximize the performance of the MARIO. Final performance of the MARIO was evaluated 
both by its ability to correctly order cases along the diagnostic spectrum from low to high risk, and its 
ability to correctly predict diagnostic categories.  
In order to add additional context to the MARIO, the frequency of five defined cell phenotypes 
was evaluated across three ranges of the MARIO score. The selected cell phenotypes included: A) large, 
normal-appearing squamous cells; B) medium-sized cells with enlarged nuclei (higher nuclear-cytoplasmic 
ratios); C) small, highly circular cells; D) lymphocytes (reflecting the inflammatory microenvironment); and 
E) lone nuclei, a sign of high grade disease. Using a training set of these manually-identified cell 
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ヮｴWﾐﾗデ┞ヮWゲが さゲｷﾏｷﾉ;ヴざ IWﾉﾉゲ ┘WヴW W┝デヴ;IデWS aヴﾗﾏ デｴW WﾐデｷヴW ゲｷﾐｪﾉW-cell database by iteratively computing a 
similarity matrix based on the Euclidean distance between objects in the single-cell database and the 
training set (dist function in the proxy[14] package in R). The cellular features used to compute the 
similarity matrix were restricted to 42 parameters that covered cellular and nuclear morphometry and 
ゲデ;ｷﾐｷﾐｪ ｷﾐデWﾐゲｷデ┞く A ﾏ;ﾐ┌;ﾉ I┌デﾗaa aﾗヴ デｴW さゲｷﾏｷﾉ;ヴｷデ┞ ヴ;ﾐｪWざ ┘;ゲ デ┌ﾐWS デﾗ Iﾗﾐaｷヴﾏ デｴW ｷﾐデWｪヴｷデ┞ ﾗa ヴWデ┌ヴﾐWS 
cells by only selecting objects with an arbitrary distance less than 50 to the target cell. Cell phenotypes 
were aggregated into frequency plots for three ranges of the MARIO covering low (0-30), medium (30-
60), and high (60-100) risk scores. 
Furthermore, the ability of the MARIO to respond to subtle changes at the single cell level was 
evaluated by simulating changes in cytology sample composition. In this simulation, 10 randomly selected 
normal patients with no clinical lesions had a percentage of archived cells from their cytology samples 
randomly exchanged with cells from a pooled set of 25 OSCC patient cytology samples, ranging from 1% 









Using data acquired from a ﾉ;ヴｪW さI┞デﾗﾉﾗｪ┞-on-Iｴｷヮざ S;デ;H;ゲWが ; ゲｷﾏヮﾉWが continuous Multivariate 
Analytical Risk Index for Oral Cancer was developed. In this previous study, data was collected according 
to the following summary: Patients presenting with one or more suspicious lesions received a non-
ｷﾐ┗;ゲｷ┗W さHヴ┌ゲｴ ゲ;ﾏヮﾉWざ ﾗa デｴW ﾉWゲｷﾗﾐ ゲ┌ヴa;IW ふFigure 1.Ia); layers of cells collected from the brush were 
vortexed and processed through a microfluidic cartridge (Figure 1.Ib) containing an embedded nano-
porous membrane (Figure 1.Ic) which captured and isolated single cells for fluorescent biomarker 
labeling; single-cell data with approximately 300 cytomorphometric parameters were extracted from 
multispectral fluorescence images of the membrane surface (Figure 1.Id), after automated image 
analysis algorithms identified cellular boundaries (Figure 1.Ie) and their corresponding regions (Figure 
1.If).While this previous study focused on the parameter selection of various binary models (Figure 
1.IIa), the MARIO developed in this study exists on a continuous-scale similar to the theoretical 
diagnostic spectrum.  
Of the six base classification models, the Lasso models differentiating classes with greater 
separation along the diagnostic spectrum outperformed those discerning classes with less separation (e.g. 
Benign / Malignant MSE = 0.2049 (± 0.86), Dysplastic/ Malignant MSE = 1.8852 (± 4.75), Supplementary 
Table 1). Following pairwise coupling, within the model training dataset, the overall classification accuracy 
based on majority class probabilities was 75%. Of the 25% misclassified observations, 71% achieved the 
correct classification by their second greatest class probability. Therefore, 93% of the true classification 
labels can be explained with the information contained in the two largest class probabilities. Final 







Table 1. Performance of the continuous MARIO was evaluated by its ability to correctly rank class 
labels in order of increasing risk on the diagnostic spectrum and its ability to correctly predict diagnostic 
class categories.  
The ability of the MARIO to correctly order all observations was evaluated by “ヮW;ヴﾏ;ﾐげゲ ヴ;ﾐﾆ 
correlation coefficient on a scale from -1 to 1 where 1 implies perfect ordering in a monotonic, but not 
necessarily linear, increasing relationship. “ヮW;ヴﾏ;ﾐげゲ coefficient value for the rank-order of class labels 
was 0.827 for the training dataset and 0.805 for the test dataset, demonstrating a strong positive 
relationship between the MARIO and position along the diagnostic spectrum. The ability of the MARIO to 
correctly predict diagnostic class categories was evaluated by discretizing the continuous score back into 
four distinct categories. Optimal cut-points were determined by minimizing class entropy by the minimum 
description length principle (MDLP). [15] The process of aggregating discrete class probabilities into a 
continuous variable was associated with a minor decrease in overall accuracy of 6.4% in the test dataset 
(from 79.2% to 72.8%). In terms of diagnostic performance, lesions at the low and high end of the disease 
spectrum were more likely to be correctly classified by the MARIO than intermediate dysplastic cases. For 
example, Normal and Malignant cases resulted in MARIO sensitivity/specificity values of 100%/96.8% and 
87.5%/89.9% in the test dataset, respectively while Benign and Dysplastic cases resulted in 
sensitivity/specificity values of 55.6%/96.8% and 73.3%/83.6% for the test dataset, respectively. 
After performance values for the training and test datasets were recorded, the MARIO model was 
applied to all patients and plotted against their gold-standard diagnoses (Figure 2). Boxplots of patient 
risk scores demonstrated a strong positive relationship against the original patient diagnoses based on 
the 2005 WHO criteria. [16] Average risk scores for confirmed normal (n=125) and OSCC (n = 65) lesions 
were significantly different from all other categories (unpaired t-test, p < 0.0001). Average scores for 
patients with benign (n = 253), mild (n = 40), moderate (n=13), and severe dysplasia (n = 10) were not 
significantly discernable from each other (unpaired t-tests, p = 0.0758 - 0.5619). At the 4-class level, where 
dysplasia cases were grouped into a single category, risk score means for each group were significantly 
different except between patients in Benign (n = 253) and Dysplastic (n = 63) classes (unpaired t-test, 306 
df, p = 0.2297). Cut-points for the MARIO on a scale from 0 to 100 were defined at positions 4, 25, and 75, 
resulting in classification intervals of 0-4 for Normal, 4-25 for Benign, 25-75 for Dysplastic, and 75-100 for 
Malignant. The large score range for the dysplastic category agrees well with conventional OED grading 
[16] given the aggregation of low, moderate, and severe/CIS dysplastic cases into a single category which 
in reality represent a range of disease severity and an accumulation of genetic alterations. 
Frequencies of different cellular phenotypes across three regions of the MARIO spectrum are 
shown in Figure 3 panel II. Progression of the MARIO from 0 to 100 was associated with a change in the 
distribution of the five cell phenotype categories. Phenotypes B (Medium-sized rounded cells with 
enlarged nuclei), C (Small, highly-circular cells), and D (lymphocytes) displayed the greatest increase in 
frequency for increasing MARIO values. Notably, the greatest increase in phenotype frequency occurred 
between the medium and high-risk score ranges, exemplified by the 4x increase in frequency of 
phenotype C and the almost 2x increase of phenotype D. Lymphocyte frequency (phenotype D) in patient 
samples for medium range risk scores was lower than both low and high range scores. While most of the 
five phenotypes increased in frequency at higher risk score values, the large, normal-appearing squamous 
cells (phenotype B) dropped in frequency approximately 30%. This ability to summarize the frequency of 
various cell phenotypes on an individual patient level has the potential to enhance molecular-level insights 
behind carcinogenesis and the malignant transformation of OPMDs. 
In addition to phenotype frequency, a simulation was conducted to evaluate the response of the 
MARIO to subtle changes at the single cell level within patient cytology samples (Figure 3, panel III). Each 
of the 10 lesion-free patients randomly selected in this exercise are represented as a line where the 
median calculated MARIO across 10 iterations is plotted against the percentage of reassigned cells. All 
patients exhibited a marked increase in MARIO ゲIﾗヴW ゲｴﾗヴデﾉ┞ ;aデWヴ ﾏﾗヴW デｴ;ﾐ ｴ;ﾉa ﾗa デｴW ヮ;デｷWﾐデゲげ IWﾉﾉゲ 
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were replaced with cells from pooled OSCC samples. This simulation also indicates that the calculation of 
the MARIO is sensitive enough to track changes in a cytology sample when only a small percentage of cells 






When evaluating patients with OPMDs, pathologists face the challenge of imposing artificial 
categories on a continuous biological process which can result in potential bias and missed opportunities 
to signify cases that may not conform to a particular classification. Though these categories were required 
to train this MARIO, we hypothesize that multiple binary classification models along the diagnostic 
spectrum can be combined into a single continuous measure to enable clinicians to monitor OPMDs in 
more detail. A continuous risk score for OPMDs computed from non-invasive cellular measurements could 
be leveraged for a multitude of applications including monitoring patient response to treatment, 
determining when to refer a patient for initial biopsy or re-biopsy, mapping the oral mucosa for signs of 
recurrence, evaluating novel therapeutics and devices in clinical trials, or determining when to initiate 
more aggressive surgical intervention.  
While achieving an overall accuracy of 72.8% that rivals expert pathologist accuracy of 69% in 
classifying OPMDs, [17] the MARIO developed here demonstrated variable performance depending on 
the region of the diagnostic spectrum. As desired, the ability to accurately distinguish normal mucosa from 
reactive benign conditions and various grades of epithelial dysplasia resulted in excellent performance 
(sensitivity = 96.5%, specificity = 96.8%, test dataset). At the other end of the diagnostic spectrum, the 
MARIO was accurately able to distinguish malignant lesions from non-malignant lesions in 89.6% of the 
cases in the test dataset.  
The lower sensitivity of Benign classification compared to other categories is due in part to the 
challenge of distinguishing particular benign inflammatory and ulcerative lesions with reactive  epithelial 
atypia inflammatory conditions from chronic conditions and the tumor microenvironment seen in 
dysplastic or malignant lesions. Additionally, the subtle cellular changes that underscore the grading 
criteria for distinguishing benign lesions from mild dysplastic lesions have confounded pathologists in 
addition to computer algorithms, where lower inter-observer agreement and accuracy have been 
reported for low grade dysplastic lesions compared to high-grade disease.[18] Future studies will seek to 
enrich the recruitment of patients within the intermediate range of the dysplastic spectrum to develop 
models that can more accurately differentiate the subtle grades of mild, moderate, and severe dysplasia. 
Furthermore, additional molecular biomarkers and morphometric features may be incorporated to 
achieve finer molecular-level detail that reflects the altered genetic state of these low-grade lesions. 
As a supplement to the visual interpretation of the raw fluorescence cytology images, the 
frequency of five different cell phenotypes was automatically measured across low, medium, and high-
risk score values. The resulting cell frequency trends agree well with conventional assessment of oral 
cytology and histology across the diagnostic spectrum. The increase in frequency of small, highly circular 
cells and cells with enlarged nuclei has been observed previously in the literature and has been attributed 
to the decrease in the amount of cytoplasm and reduction in the degree of cellular cohesion that occurs 
with increased dysplasia  grade.[19] The high frequency of lymphocytes in the low risk score range is likely 
due to the presence of inflammatory conditions and ulcerative lesions among patients with benign 
conditions such as ulcerative and erosive lichen planus. By interactively selecting target cells and tuning 
デｴW さゲｷﾏｷﾉ;ヴｷデ┞ ヴ;ﾐｪWざが a┌デ┌ヴW ゲデ┌SｷWゲ Iﾗ┌ﾉS Wﾏヮﾉﾗ┞ デｴｷゲ ﾐﾗ┗Wﾉ IWﾉﾉ ケ┌Wヴ┞ ;ヮヮヴﾗ;Iｴ デﾗ ｷﾐ┗Wゲデｷｪ;デW ﾗヴ ﾉ;HWﾉ 
unique cell phenotypes in an effort to uncover molecular-level insights into OPMD progression. 
The ability to condense the complex biological information contained in a OPMD cytology sample 
into a single MARIO has the potential to lead to unique insights surrounding the molecular phenomena 
associated with lesion progression. While prospectively recruited OPMD samples better reflect the true 
heterogeneity of the real-world patient population, they do not offer information with regard to individual 
lesion progression over time. However, the response of the MARIO to cytology sample alterations at the 
single-cell level can be simulated by randomly exchanging cells between patients with different initial 
diagnoses.  By iterating this simulation for a sample of healthy volunteers and OSCC patients, we have 
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observed that the MARIO is capable of tracking changes in a cytology sample when only a small percentage 
of cells display a morphometric or biomarker expression alteration. 
The MARIO presented here was recently used in a retrospective study involving cytology-on-chip 
measurements from a high-risk population of patients with Fanconi Anemia (FA), a rare inherited 
chromosomal instability disorder associated with an 800-times higher risk of developing oral cancer than 
the general population. [20,21] Cytology-on-chip samples from 37 FA patients over two recruitment 
cohorts in the 2014 and 2016 Meeting for Adults with FA were used to compute their MARIO scores, 
including six patients who presented at both meetings, representing a monitoring period of two years. Of 
these six patients, MARIO scores increased significantly (+>40%) for two patients, suggesting progression; 
decreased (->40%) for two patients, suggesting non-progression or regression; and remained unchanged 
for the remaining two patients (+/- 5%), indicating non-progression or stable disease. [22] One of the first 
two patients demonstrated a 27-fold increase in their MARIO, self-reported a recent pharyngeal cancer 
diagnosis within the 2-year period, and was notified to seek additional guidance from the ヮ;デｷWﾐデげゲ ｴW;S 
and neck surgeon. This small pilot, proof-of concept study demonstrated that the MARIO score has 
potential to predict accurately the malignancy risk of OPMD in two patients as confirmed by follow-up 







We have demonstrated that a multi-class classifier can be adapted to achieve a single, continuous 
さゲW┗Wヴｷデ┞ ゲIﾗヴWざ while achieving high performance (72.8% overall accuracy, individual class prediction 
accuracy from 76.0% - 97.6%) to provide clinicians with a metric to track OPMD progression at the patient 
level using non-invasive sampling. While the application to oral medicine and the assessment of OPMD 
have been emphasized, this methodology could be generalized to other medical applications. Future 
efforts will focus on evaluating this MARIO for monitoring patients over time. Based on robust 
performance agreement between the model development and test datasets (±1.7% in terms of accuracy), 
these methods are anticipated to generalize well with future collected data. Further optimization of these 
models is possible with future studies involving a larger number of patients with dysplastic lesions. An 
intriguing, bold visualization of a single metric representing thousands of single-cell morphometric and 
molecular attributes has been demonstrated with potential to efficiently assess the degree of progression 




FIGURES AND TABLES 
 
 
Figure 1 - Rｷゲﾆ ゲデヴ;デｷaｷI;デｷﾗﾐ Sｷ;ｪヴ;ﾏ ;ﾐS さC┞デﾗﾉﾗｪ┞-on-Iｴｷヮざ ┘ﾗヴﾆaﾉﾗ┘く Panel I: A) Suspicious lesion is sampled via 
さHヴ┌ゲｴ ゲ;ﾏヮﾉWざ デWIｴﾐｷケ┌Wが BっCぶ ゲｷﾐｪﾉW IWﾉﾉゲ ;ヴW I;ヮデ┌ヴWS ﾗﾐ ; ﾐ;ﾐﾗ-porous membrane embedded within a 
microfluidic channel, D) multispectral fluorescence images are recorded across a raster-scan of the membrane, E) 
algorithms identify cellular boundaries based on signal contrast, and F) regions of interest (ROIs) are extracted for 
quantification. Panel II: The 7-stage diagnostic spectrum proposed by the 2005 WHO guidelines [25] displayed as a 
continuous number line. A) Binary risk assessment in the primary clinical setting scenario, where the main goal is to 










Table 1 - MARIO performance of the training and test datasets  
 
 Training Set (75% of data) Test Set (25% of data) 
Max Score Vote (Accuracy, %) 79.80% 79.02%  
Class Binning (Accuracy, %) 74.54% 72.80% 
VﾗデW OヴSWヴ ふ“ヮW;ヴﾏ;ﾐげゲ ヴｴﾗぶ 0.876 0.886 














Normal 97.37 100.00 96.52 0.983 97.60 100.00 96.81 0.984 
Benign 78.74 59.47 97.91 0.787 76.00 55.56 96.78 0.762 
Dysplastic 82.68 72.92 84.01 0.785 82.40 73.33 83.64 0.785 







Figure 2 - MARIO Performance. Barplots scaled to class densities (y-axis) across the MARIO (x-axis) for (A) Training 
and (B) Test datasets. Color-coding represents the true patient class according to histopathology. Vertical dashed 
lines represent optimal cut-points for discretizing the continuous score into disease class domains based on 
minimizing class entropy in the training dataset. C) Box-plot of MARIO values (y-axis) across the 6 different diagnostic 





Figure 3 - Results from single-cell calibration exercise and phenotype query. Panel I) Representative images of cell 
phenotypes for frequency tables in Panel II: A) Medium-sized rounded cell with enlarged nuclei, B) Large, normal-
appearing squamous cell, C) Small, highly-circular cell, D) Leukocyte, E) lone nuclei. Panel II) Distribution of phenotype 
frequencies for patients with the identified range of risk scores (Blue: 0-25, Orange: 30-60, Red: 75-100). Left axis = 
A, B; Right axis = C, D, E. Error bars = standard deviation of phenotype frequency per patient. Panel III: Results from 
cell reassignment simulation where solid lines represent median MARIO values for each of 10 randomly selected 
healthy volunteer samples across the increasing percentage of their cells exchanged for cells from a corpus of OSCC 






 OPMD に Oral Potentially Malignant Lesion(s) 
 OED に Oral Epithelial Dysplasia 
 OSCC  - Oral Squamous Cell Carcinoma 
 AUC に Area Under the ROC (receiver-operator characteristic) Curve 
 FA に Fanconi Anemia 
 MSE に Mean Squared Error 
 MDLP に Minimum description length principle  
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